Teva

SHERIDAN, WYOMING - March 04, 2026 - Teva has secured $400 million in funding from Blackstone Life Sciences to advance duvakitug, a Sanofi-partnered TL1A blocker in development for inflammatory bowel diseases. The financing is structured to be disbursed over four years and includes regulatory and undisclosed commercial milestones, plus low single-digit royalties on worldwide sales. For Teva, the deal adds non-dilutive-style runway and a clearer capital path for a program that already has defined Phase 3 responsibilities with Sanofi. For operators, it underscores how external capital is increasingly being used to sustain late-stage clinical programs while preserving strategic partnerships and commercialization options.